Casper Pharma Profile
Key Indicators
- Authorised Capital ₹ 26.10 Cr
as on 30-07-2024
- Paid Up Capital ₹ 26.08 Cr
as on 30-07-2024
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 4.69%
(FY 2023)
- Profit -41.49%
(FY 2023)
- Ebitda -37.68%
(FY 2023)
- Net Worth 21.60%
(FY 2023)
- Total Assets 16.73%
(FY 2023)
About Casper Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 26.10 Cr and a paid-up capital of Rs 26.08 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Casper Pharma Private Limited India are Satish Agarwal as COMPANY SECRETARY and Srihari Sadhu as Cfo. Sudhir Singh, Venkatanaga Raju, and Hanumantha Kokkonda serve as directors at the Company.
- CIN/LLPIN
U24233MH2016PTC423891
- Company No.
102713
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jan 2016
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Casper Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satish Agarwal | Company Secretary | 13-Nov-2017 | Current |
| Srihari Sadhu | CFO | 04-May-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhir Singh  | Whole-Time Director | 26-Dec-2023 | Current |
| Venkatanaga Raju | Director | 26-Dec-2023 | Current |
| Hanumantha Kokkonda | Director | 04-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Casper Pharma.
Casper Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.69% increase. The company also saw a substantial fall in profitability, with a 41.49% decrease in profit. The company's net worth Soared by an impressive increase of 21.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Casper Pharma?
In 2023, Casper Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Casper Pharma?
Casper Pharma has a workforce of 100 employees as of Jul 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Casper Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Casper Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
